The American healthcare system has no shortage of reform proposals. Across the ideological spectrum, from incremental adjustments to structural transformation, serious people with relevant expertise have developed detailed, technically grounded proposals for changing the system — how coverage is financed, how prices are set, how administrative complexity is managed, how long-term care is funded, how behavioral health is integrated, how pharmaceutical pricing is regulated. The proposals exist. The analytical work behind them exists. What has been missing, as Why Healthcare Reform Keeps Failing documents, is not ideas but the organizational infrastructure to sustain pressure for implementation across administrations and the political conditions to move from proposal to law.
This article describes the landscape of serious reform proposals without advocating for any specific approach. The proposals range from changes that work within the existing multi-payer structure to changes that would transform the structure itself. They differ in what they would cost, who would bear those costs, how they would affect existing coverage arrangements, and what the transition from the current system to the proposed one would require. Reasonable people with relevant expertise and genuine concern for outcomes disagree substantially about which approaches would produce the best results, and that disagreement deserves deliberation rather than resolution by assertion.
The structural models through which other countries have achieved universal coverage — the evidence base for evaluating what different structural approaches produce — are examined in How Other Countries Have Achieved Universal Coverage. What universal coverage would mean as a policy outcome, and what different paths to it would require, is in What Universal Coverage Would Actually Mean. This article maps the specific reform proposals active in the current American policy debate.
Single-Payer: Medicare for All
The most structurally transformative proposal in the current American reform debate is Medicare for All — the expansion of the Medicare framework to cover the entire population, replacing employer-sponsored insurance, Medicaid, the ACA marketplaces, and most other existing coverage with a single federally administered program.
The most detailed legislative version has been developed in the Senate by Senator Bernie Sanders and in the House by Representative Pramila Jayapal. The core features are: universal enrollment of all residents, coverage of a comprehensive benefit package that includes medical, dental, vision, hearing, mental health, and long-term care, elimination of premiums and most cost-sharing at the point of service, and a single federal payer that negotiates with providers and sets payment rates. The proposal would be financed through new federal taxes — the specific financing mechanisms vary across versions, but typically include payroll taxes, income taxes on high earners, and taxes on financial transactions.
The case for single-payer rests on several structural arguments. Administrative simplification — eliminating the billing complexity of the multi-payer system — would reduce overhead significantly, with estimates of administrative savings ranging from several hundred billion to over a trillion dollars annually, depending on methodology. The single payer’s market power in negotiating provider rates and pharmaceutical prices would reduce what is paid per unit of service. Universal enrollment would eliminate the access barriers and health harms of the coverage gap. And the comprehensive benefit package, including long-term care, would address coverage gaps that no other reform proposal fully addresses.
The case against single-payer, or for proceeding cautiously, rests on several concerns that are not primarily ideological. The displacement of employer-sponsored insurance — which covers approximately 160 million Americans, many of whom are satisfied with their coverage — is a politically and practically complex transition. Provider payment rates under single-payer would likely be substantially lower than current commercial rates, with significant consequences for hospital revenues, physician incomes, and the financial viability of practices and facilities built around commercial insurance payment. The federal financing required is large, and while proponents argue that total spending would decrease as employer and individual premiums are replaced by taxes, the redistribution of who pays what would produce winners and losers whose political salience varies. And implementation of a system of this scale and complexity — replacing multiple existing systems simultaneously — poses administrative challenges that are real even if they are manageable in principle.
Public Option
A public option — a government-administered insurance plan that competes with private insurers in the same market — has been the most frequently proposed reform in recent legislative and executive branch discussions. Multiple versions have been introduced in Congress, and the Biden administration’s initial healthcare platform included a public option as its central healthcare proposal.
The basic structure is a government plan available to people who lack employer-sponsored coverage or who choose to leave employer coverage, priced at rates that reflect the government’s lower administrative overhead and greater market power relative to private insurers. The public option would compete with private plans in the ACA marketplaces and potentially in the employer market.
Public option proposals vary significantly in their specifics in ways that matter substantially for their effects. The payment rates the public plan uses — whether it pays Medicare rates, rates negotiated above Medicare, or rates negotiated independently — determine both how affordable the plan is relative to private alternatives and how much financial disruption it creates for providers whose revenues depend on commercial rates. Whether employers can offer the public option to their workers determines whether it could gradually absorb the employer-sponsored population. Whether the public option is available universally or only to people without other coverage options determines how much competitive pressure it places on private insurers.
The strategic political argument for a public option over single-payer is that it is less disruptive to existing coverage arrangements — it does not force anyone out of employer-sponsored insurance, it does not displace private insurers from the market, and it does not require the complete restructuring of healthcare financing. The strategic policy argument against a public option — from both the left and the right — is that it creates an unstable hybrid: too disruptive to leave the private market intact, not transformative enough to capture the administrative savings of a unified system. Proponents of single-payer argue that a well-designed public option would gradually crowd out private insurance as its lower costs attracted enrollment, making it a transitional path to single-payer. Opponents of expanded public coverage argue that the public option would crowd out private insurance through unfair government competition, producing de facto single-payer through attrition rather than democratic choice.
ACA Expansion and Stabilization
Short of structural transformation, there is a substantial reform agenda that works within the existing ACA framework to extend and deepen its coverage gains, address its remaining gaps, and stabilize the insurance markets it created.
The remaining Medicaid expansion gap — the states that have not expanded Medicaid, leaving millions of low-income adults without coverage in states with the most restrictive pre-expansion eligibility — represents the most straightforward available coverage extension. The evidence that Medicaid expansion improves health outcomes, reduces medical debt, and stabilizes rural hospitals is robust. Federal incentives to encourage holdout states to expand have been included in recent legislation; more aggressive inducements, including reducing other federal healthcare funding to states that refuse expansion, have been proposed but not enacted.
Premium subsidy expansion — extending the enhanced ACA subsidies enacted in the American Rescue Plan to higher income levels and making them permanent — would reduce the cost of marketplace coverage for middle-income people who currently find it expensive. The enhanced subsidies enacted in 2021 have produced significant enrollment growth and demonstrated that subsidy generosity is a primary determinant of marketplace enrollment levels.
Closing the family glitch — the rule that tied family coverage eligibility for ACA subsidies to whether the worker’s own coverage was affordable, rather than whether family coverage was affordable — was addressed by regulatory action in 2022. Other regulatory and legislative fixes to ACA market rules that produce coverage gaps or market instability have been identified and partially addressed.
The limitation of ACA expansion and stabilization as a reform strategy is that it addresses the coverage structure without addressing the cost structure — the pricing system, the administrative overhead, the consolidation dynamics, and the pharmaceutical pricing mechanisms that drive healthcare costs upward in ways the ACA did not touch. Coverage expansion within the existing cost structure makes coverage more affordable to individuals through subsidies while leaving intact the underlying prices that make the system expensive.
Price Reform: All-Payer Rate Setting
Price reform — changing the mechanisms by which healthcare prices are set — addresses the cost problem more directly than coverage reform. The most structurally significant price reform proposal is all-payer rate setting: a system in which all payers — Medicare, Medicaid, commercial insurers, and self-pay patients — pay the same negotiated rates for the same services, set through a public process rather than through confidential bilateral negotiation.
Maryland has operated an all-payer hospital rate setting system since the 1970s — the only state with such a system. Under Maryland’s model, a state commission sets the rates that all payers pay to hospitals, eliminating the variation between commercial, Medicare, and Medicaid rates that characterizes the rest of the country. The Maryland system has produced cost growth below the national average and provided a stable financial environment for rural hospitals that have remained open in Maryland at higher rates than in comparable states.
The arguments for all-payer rate setting are several: it eliminates the cross-subsidy dynamic in which commercial insurance rates compensate for low government rates, it gives rural and safety-net hospitals a more stable revenue base, it reduces the administrative complexity of managing multiple different rate contracts, and it constrains provider pricing power by replacing bilateral negotiation with a public rate-setting process. The arguments against it, or for caution about extending it nationally, include concerns about government interference in private market pricing, the difficulty of setting rates at the right level across the enormous variation in provider costs and markets nationwide, and the political resistance of providers who benefit from the current variation in rates.
Pharmaceutical Pricing Reform
Pharmaceutical pricing reform is a distinct reform track with its own proposals and its own political economy. The Inflation Reduction Act of 2022 represented the first significant federal action on pharmaceutical pricing in Medicare since the creation of Medicare Part D in 2003 — granting Medicare authority to negotiate prices for a small number of high-cost drugs and requiring that price increases for existing drugs not exceed inflation.
The IRA’s negotiation authority is real and its effects on the specific drugs covered are significant, but its scope is limited: it covers a small and slowly growing number of drugs, and it applies only to Medicare, not to the commercial market or Medicaid. Proposals to extend negotiation authority to more drugs, to remove the statutory cap on the number of drugs eligible for negotiation, and to extend negotiation results to the commercial market would expand the scope substantially.
Reference pricing — setting pharmaceutical prices in the United States based on prices paid in peer countries — has been proposed as an alternative or complement to direct negotiation. Most peer countries set drug prices through reference pricing mechanisms that benchmark against prices in other reference countries; the United States is an outlier in not using reference pricing. The practical and legal complexity of implementing reference pricing in the U.S. context is real, but the mechanism is well-established in peer countries and has strong evidence of effectiveness in constraining manufacturer pricing power.
Reforms to the patent and exclusivity system — which determines how long manufacturers can sell drugs without generic competition — represent another track. Patent term extensions, secondary patents on minor modifications to existing drugs, and the settlement agreements between branded and generic manufacturers that delay generic entry have extended the monopoly period for many drugs substantially beyond what patent law’s original intent would suggest. Reforming these practices — restricting secondary patents, ending pay-for-delay settlements, reforming the exclusivity periods for biologic drugs — would accelerate generic and biosimilar competition and reduce prices through competition rather than through negotiation.
Long-Term Care Financing Reform
Long-term care financing is the largest gap in the American healthcare coverage system and the one with the most certain demographic trajectory — the demand for long-term care will increase substantially as the baby boom generation ages into the range of highest need. It is also the gap with the fewest active reform proposals proportionate to its scale.
The WISH Act — the Well-Being Insurance for Seniors to be at Home Act — and similar proposals would create a federal long-term care insurance program providing a limited cash benefit for people who meet functional eligibility criteria. The benefit would not cover the full cost of long-term care but would supplement personal resources and family caregiving in ways that reduce the catastrophic spend-down that currently characterizes the system for middle-income families.
The CLASS Act — the Community Living Assistance Services and Supports Act — was included in the ACA but never implemented after the Department of Health and Human Services determined that it could not be made actuarially sound as a voluntary program. The CLASS Act’s failure illustrated the fundamental actuarial challenge of voluntary long-term care insurance: voluntary enrollment produces adverse selection — the people who enroll are disproportionately likely to need benefits — which drives premiums high, which drives away lower-risk enrollees, which drives premiums higher still.
Universal or near-universal long-term care coverage — the model used by Germany, Japan, the Netherlands, and several other peer countries — avoids the adverse selection problem through mandatory enrollment. The financing of such a program — through dedicated payroll taxes, as in Germany and Japan, or through general revenues, as in some other countries — is a genuine fiscal challenge at the scale of U.S. long-term care need. The scale of the challenge is not a reason to ignore it; the demographic arithmetic makes delay increasingly costly.
Administrative Simplification
Administrative simplification — reducing the overhead generated by the multi-payer billing system without changing the overall coverage structure — is a reform track that has support across ideological lines and that could produce significant savings within the existing system.
Standardization of prior authorization requirements — uniform criteria, timelines, and appeals processes across all payers — would reduce the burden of the authorization system on physicians and patients without eliminating insurer authority to manage utilization. The Improving Seniors’ Timely Access to Care Act, which established prior authorization requirements for Medicare Advantage plans, represents one model; extension to commercial insurance would require federal or state action.
Standardization of billing and credentialing — uniform billing codes, forms, and credentialing requirements across all payers — would reduce the administrative complexity of managing multiple payer relationships without requiring the elimination of multiple payers. The efficiency gap between the American administrative system and the systems of countries with regulated multi-payer structures reflects partly the absence of standardization that regulation could provide within the existing multi-payer structure.
Price transparency — requirements that hospitals and insurers publish the prices actually paid for services — has been advanced through regulation and represents an attempt to introduce market information into a system that has operated in opacity. As noted in How the Pricing System Works Against Patients, transparency requirements to date have produced technically available information that is practically inaccessible to most patients. More accessible transparency — usable by patients and employers to compare prices before seeking care — would require additional standardization of how price information is published and presented.
Behavioral Health Integration
Behavioral health integration — the structural incorporation of mental health and addiction treatment into the primary healthcare system — is a reform track with a substantial evidence base and a set of specific policy levers that have not been fully engaged.
Parity enforcement with meaningful teeth — federal and state regulatory action that goes beyond technical compliance to address the practical coverage failures documented in Mental Health and Addiction: The Integration Failure — is the most direct available lever. Network adequacy standards for behavioral health that are actually enforced, audits of prior authorization practices that identify disparities between behavioral health and medical authorization rates, and meaningful penalties for parity violations would move the behavioral health coverage picture closer to what the law has required since 2008 but not achieved.
Payment reform for integrated care — codes and reimbursement for care coordination between behavioral health and medical providers, expansion of Collaborative Care Model reimbursement, and global payment models that create financial incentives for integration rather than fragmented fee-for-service billing — would address the structural payment misalignment that makes integrated care financially difficult to sustain.
Workforce expansion for behavioral health — loan forgiveness for behavioral health providers, graduate medical education funding for psychiatry residencies, scope of practice reforms that allow psychologists, advanced practice nurses, and physician assistants to prescribe psychiatric medications with appropriate training — would address the supply shortage that makes integration operationally difficult even where the financial incentives exist.
What the Landscape Reveals
Mapping the full range of reform proposals reveals several things about the structure of the healthcare reform debate that are worth naming explicitly.
The proposals are not mutually exclusive in all cases. Administrative simplification can proceed within any coverage structure. Pharmaceutical pricing reform is independent of the coverage question. Behavioral health integration can be advanced under existing coverage arrangements while structural coverage reform is debated. Long-term care financing is a gap that all coverage structures leave — single-payer, public option, and ACA expansion proposals all require separate action on long-term care. The tendency of healthcare reform debate to frame choices as binary — Medicare for All or the status quo, public option or private insurance — obscures the extent to which reform tracks can and should proceed in parallel.
The proposals also differ in what constraints they face. Some face primarily technical and actuarial challenges — the design questions about benefit packages, payment rates, and transition mechanisms. Some face primarily political challenges — the organized opposition of interests that benefit from current arrangements. Some face both. Understanding which constraint is binding for which proposal is necessary for thinking clearly about what is achievable in what sequence.
The people whose experience should most inform these choices — the patients who have been harmed by the current system’s failures, the providers who navigate its dysfunctions daily, the caregivers managing the long-term care gap, the workers whose wages are constrained by administrative overhead rather than clinical investment — are the least represented in the policy processes that have produced and will evaluate these proposals. Building the organizational infrastructure that gives those voices sustained presence in the reform conversation is part of what this hub is for.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.